# US 2021/0139862 A1 · NOVEL 7Beta-HYDROXYSTEROID DEHYDROGENASE MUTANTS AND PROCESS FOR THE PREPARATION OF URSODEOXYCHOLIC ACID

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0139862 A1
- Document ID: US20210139862A1
- Status: Published application
- Kind: A1
- Application number: 17/150,243
- Filed: 2021-01-15
- Published: 2021-05-13
- Earliest claimed: 2010-12-16
- Assignees: PharmaZell GmbH
- Applicants: PharmaZell GmbH
- Inventors: Dirk Weuster-Botz; Michael Braun; Arno Aigner; Boqiao Sun; Christina Kantzow; Sven Bresch; Daniel Bakonyi; Werner Hummel
- Web page: https://patentgrep.com/patent/US20210139862A1

## CPC

- C12N 9/0006: {acting on CH-OH groups as donors (1.1)}
- C12N 9/0008: {acting on the aldehyde or oxo group of donors (1.2)}
- C12P 33/00: Preparation of steroids
- C12P 33/02: Dehydrogenating; Dehydroxylating
- C12Y 101/01201: 7-Beta-hydroxysteroid dehydrogenase (NADP+) (1.1.1.201)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Y: ENZYMES

## Abstract

In various aspects and embodiments, the invention provides a nucleic acid molecule comprising a nucleotide sequence encoding a 7β-hydroxysteroid dehydrogenase (7β-HSDH) mutant that catalyzes at least the stereospecific enzymatic reduction of a 7-ketosteroid to the corresponding 7-hydroxysteroid, wherein the mutant has, compared to the wildtype 7β-HSDH of SEQ ID NO:2, a decreased substrate inhibition and/or an altered cofactor usage, and the mutant has, in comparison with the wildtype 7β-HSDH of SEQ ID NO:2, 1 to 15 amino acid additions, substitutions, deletions and/or inversions in the sequence motif VMVGRRE corresponding to positions 36 to 42 of SEQ ID NO:2.

## Claims

### Claim 1

A nucleic acid molecule comprising a nucleotide sequence encoding a 7β-hydroxysteroid dehydrogenase (7β-HSDH) mutant that catalyzes at least the stereospecific enzymatic reduction of a 7-ketosteroid to the corresponding 7-hydroxysteroid, wherein the mutant has, compared to the wildtype 7β-HSDH of SEQ ID NO:2, a decreased substrate inhibition and/or an altered cofactor usage, and the mutant has, in comparison with the wildtype 7β-HSDH of SEQ ID NO:2, 1 to 15 amino acid additions, substitutions, deletions and/or inversions in the sequence motif VMVGRRE corresponding to positions 36 to 42 of SEQ ID NO:2.

### Claim 2 (depends on 1)

The nucleic acid molecule of claim 1, wherein the mutant has at least one mutation in the sequence motif VMVGRRE according to position 36 to 42 of SEQ ID NO:2 and at least 90% sequence identity to SEQ ID NO:2.

### Claim 3 (depends on 1)

A recombinant microorganism comprising at least one nucleic acid sequence coding for the mutant of claim 1, at least one corresponding expression cassette, or at least one corresponding vector.

### Claim 4 (depends on 1)

A process for enzymatic or microbial synthesis of 7β-hydroxysteroids, comprising reacting the corresponding 7-ketosteroid in the presence of a 7β-HSDH mutant of claim 1 or in the presence of a recombinant microorganism expressing said mutant, wherein at least one reduction product is formed.

### Claim 5 (depends on 4)

The process of claim 4, wherein reduction takes place in the presence of NADPH and/or NADH.

### Claim 6 (depends on 5)

The process of claim 5, further comprising:
a) regenerating spent NADPH by coupling with an NADPH-regenerating enzyme selected from the group consisting of NADPH dehydrogenases, alcohol dehydrogenases (ADH), NADPH-regenerating formate dehydrogenases (FDH) and NADPH-regenerating glucose dehydrogenases (GDH; and/or b) regenerating spent NADH by coupling with an NADH-regenerating enzyme selected from the group consisting of NADH-dehydrogenases, NADH-regenerating formate dehydrogenases (FDH), NADH-regenerating alcohol dehydrogenases (ADH), NADH-regenerating glucose-6-phosphate-dehydrogenases (G6PDH), NADH-regenerating phosphite dehydrogenases (PtDH) and NADH-regenerating glucose dehydrogenases (GDH).

### Claim 7 (depends on 6)

The process of claim 6, wherein the NADPH-regenerating enzyme is selected from the group consisting of mutants of an NAD+-dependent formate dehydrogenase (FDH) that at least catalyze the enzymatic oxidation of formic acid to CO2, wherein the mutants, compared to the nonmutated enzyme accept NADP+ as cofactor.

### Claim 8 (depends on 7)

The process of claim 7, wherein the NADP+-accepting FDH mutant has at least one mutation in the amino acid sequence of an FDH from Mycobacterium vaccae N10 according to SEQ ID NO:36 or an amino acid sequence derived therefrom with at least 90% sequence identity to SEQ ID NO:36.

### Claim 9 (depends on 7)

The process of claim 7, wherein the NADP+-accepting mutant has at least one mutation in the sequence motif TDRHRL according to position 221 to 226 of SEQ ID NO:36 or in the corresponding sequence motif of an amino acid sequence derived therefrom with at least 90% sequence identity to SEQ ID NO:36.

### Claim 10 (depends on 1)

A nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of nucleic acid sequences that:
a) simultaneously encode an FDH mutant of an NAD+-dependent formate dehydrogenase (FDH) that at least catalyzes the enzymatic oxidation of formic acid to CO2, wherein the mutant, compared to the nonmutated enzyme, accepts NADP+ as cofactor and the 7β-HSDH wildtype;
b) simultaneously encode an FDH mutant of an NAD+-dependent formate dehydrogenase (FDH) that at least catalyzes the enzymatic oxidation of formic acid to CO2, wherein the mutant, compared to the nonmutated enzyme, accepts NADP+ as cofactor and the nonmutated 7β-HSDH wild type and optional a 3α-HSDH;
c) encode a fusion protein comprising an FDH mutant selected from the group consisting of mutants of an NAD dependent formate dehydrogenase (FDH) that at least catalyze the enzymatic oxidation of formic acid to CO2, wherein the mutant, compared to the nonmutated enzyme, accepts NADP+ as cofactor and a 7β-HSDH mutant encoded by the nucleic acid of claim 1;
d) encode a fusion protein comprising an FDH mutant selected from the group consisting of mutants of an NAD+-dependent formate dehydrogenase (FDH) that at least catalyze the enzymatic oxidation of formic acid to CO2, wherein the mutant, compared to the nonmutated enzyme, accepts NADP+ as cofactor and a nonmutated 7β-HSDH;
e) simultaneously encode an FDH wild type and a 7β-HSDH mutant encoded by the nucleic acid of claim 1;
f) encode a fusion protein, comprising the FDH wild type and a 7β-HSDH mutant encoded by the nucleic acid of claim in 1;
g) simultaneously encode a GDH and a 7β-HSDH wild type;
h) coding for a fusion protein, comprising a GDH and a 7β-HSDH wild type;
i) simultaneously coding for a GDH and a 7β-HSDH mutant encoded by the nucleic acid of claim 1; and
j) coding for a fusion protein, comprising a GDH, a 7β-HSDH mutant encoded by the nucleic acid of claim 1.

### Claim 11 (depends on 10)

A recombinant microorganism comprising at least one nucleic acid molecule of claim 10.

### Claim 12 (depends on 1)

A recombinant microorganism that simultaneously expresses:
a) the 7β-HSDH mutant encoded by the nucleic acid of claim 1, an NADP+-accepting FDH mutant and/or the corresponding FDH wild type; or
b) that simultaneously expresses a 7β-HSDH mutant and a GDH.

### Claim 13 (depends on 12)

The recombinant microorganism of claim 12, wherein the FDH mutant is selected from the group consisting of mutants of an NAD+-dependent formate dehydrogenase (FDH) that at least catalyze the enzymatic oxidation of formic acid to CO2, wherein the mutant, compared to the nonmutated enzyme, accepts NADP+ as cofactor; and wherein the FDH wild type is an FDH from Mycobacterium vaccae N10 according to SEQ ID NO:36 or an FDH derived therefrom with at least 90% sequence identity to SEQ ID NO:36.

### Claim 14 (depends on 1)

A process for preparing ursodeoxycholic acid (UDCA) of formula (1)
in which R stands for alkyl, NR1R2, H, an alkali metal ion or N(R3)4+, in which the residues R3 may be identical or different and stand for H or alkyl, wherein the process comprises:
a) reducing dehydrocholic acid (DHCA) of formula (3)
in which R has the meanings given above, in the presence of at least one 7β-HSDH mutant of claim 1 and in the presence of at least one 3α-HSDH; to the corresponding 12-keto-ursodeoxycholic acid (12-keto UDCA) of formula (4)
in which R has the meanings given above; and chemically reducing the 12-keto-UDCA of formula (4) to UDCA.

### Claim 15 (depends on 1)

A process for preparing ursodeoxycholic acid (UDCA) of formula (1); wherein R stands for alkyl, NR1R2, H, an alkali metal ion or N(R3)4+, in which the residues R3 may be identical or different and stand for H or alkyl, wherein the process comprises:
reducing dehydrocholic acid (DHCA) of formula (3) in which R has the meanings given above, in the presence of at least one 7β-HSDH mutant of claim 1 and in the presence of a recombinant organism comprising a nucleic acid molecule comprising at least one nucleic acid sequence selected from the group consisting of nucleic acid sequences that:
a) simultaneously encode an FDH mutant of an NAD+-dependent formate dehydrogenase (FDH) that at least catalyzes the enzymatic oxidation of formic acid to CO2, wherein the mutant, compared to the nonmutated enzyme, accepts NADP+ as cofactor and the 7β-HSDH wildtype;
b) simultaneously encode an FDH mutant of an NAD+-dependent formate dehydrogenase (FDH) that at least catalyzes the enzymatic oxidation of formic acid to CO2, wherein the mutant, compared to the nonmutated enzyme, accepts NADP+ as cofactor and the nonmutated 7β-HSDH wild type and optional a 3α-HSDH;
c) encode a fusion protein comprising an FDH mutant selected from the group consisting of mutants of an NAD dependent formate dehydrogenase (FDH) that at least catalyze the enzymatic oxidation of formic acid to CO2, wherein the mutant, compared to the nonmutated enzyme, accepts NADP+ as cofactor and a 7β-HSDH mutant encoded by the nucleic acid of claim 1;
d) encode a fusion protein comprising an FDH mutant selected from the group consisting of mutants of an NAD+-dependent formate dehydrogenase (FDH) that at least catalyze the enzymatic oxidation of formic acid to CO2, wherein the mutant, compared to the nonmutated enzyme, accepts NADP+ as cofactor and a nonmutated 7β-HSDH;
e) simultaneously encode an FDH wild type and a 7β-HSDH mutant encoded by the nucleic acid of claim 1;
f) encode a fusion protein, comprising the FDH wild type and a 7β-HSDH mutant encoded by the nucleic acid of claim 1;
g) simultaneously encode a GDH and a 7β-HSDH wild type;
h) coding for a fusion protein, comprising a GDH and a 7β-HSDH wild type;
i) simultaneously coding for a GDH and a 7β-HSDH mutant encoded by the nucleic acid of claim 1; and
j) coding for a fusion protein, comprising a GDH, a 7β-HSDH mutant encoded by the nucleic acid of claim 1;
to the corresponding 12-keto-ursodeoxycholic acid (12-keto UDCA) of formula (4) in which R has the meanings given above; and chemically reducing the 12-keto-UDCA of formula (4) to U DCA.

### Claim 16 (depends on 1, 12)

A process for preparing ursodeoxycholic acid (UDCA) of formula (1); wherein R stands for alkyl, NR1R2, H, an alkali metal ion or N(R3)4+, in which the residues R3 may be identical or different and stand for H or alkyl, wherein the process comprises:
reducing dehydrocholic acid (DHCA) of formula (3) in which R has the meanings given above, in the presence of at least one 7β-HSDH mutant of claim 1 and in the presence of at least once nucleic acid sequence of claim 12; to the corresponding 12-keto-ursodeoxycholic acid (12-keto UDCA) of formula (4)
in which R has the meanings given above; and chemically reducing the 12-keto-UDCA of formula (4) to UDCA.

### Claim 17 (depends on 1)

The nucleic acid molecule of claim 1, wherein the mutant has decreased substrate inhibition for a 7-ketosteroid substrate.

### Claim 18 (depends on 6)

The process of claim 6, further comprising isolating at least one reduction product from the reaction mixture.

### Claim 19 (depends on 7)

The process of claim 7, wherein the process takes place with the consumption of NADPH and/or NAD.

### Claim 20 (depends on 8)

The process of claim 8, wherein the NADH-regenerating enzyme is expressed in a recombinant microorganism.

### Claim 21 (depends on 1)

The nucleic acid molecule of claim 1, wherein the mutant has at least one mutation in the sequence motif VMVGRRE according to position 36 to 42 of SEQ ID NO:2 and at least 90% or 95% sequence identity to SEQ ID NO:2.

### Claim 22 (depends on 5)

The recombinant microorganism of claim 5, further comprising a coding sequence for an additional enzyme.

### Claim 23 (depends on 22)

The recombinant microorganism of claim 22, wherein the additional enzyme is selected from the group consisting of hydroxysteroid dehydrogenases and dehydrogenases suitable for cofactor regeneration.

### Claim 24 (depends on 23)

The recombinant microorganism of claim 23, wherein the hydroxysteroid dehydrogenase is 3α-hydroxysteroid dehydrogenase (3α-HSDH).

### Claim 25 (depends on 8)

The process of claim 8, wherein the NADPH-regenerating enzyme is expressed by a recombinant microorganism.

### Claim 26 (depends on 10)

The nucleic acid molecule of claim 10, wherein the nucleic acid sequences further encode a 3α-hydroxysteroid dehydrogenase (3α-HSDH).

### Claim 27 (depends on 12)

The recombinant organism of claim 12, that further simultaneously expresses a 3α-hydroxysteroid dehydrogenase (3α-HSDH).

### Claim 28 (depends on 13)

The recombinant organism of claim 13, that further simultaneously expresses a 3α-hydroxysteroid dehydrogenase (3α-HSDH).

### Claim 29 (depends on 15)

The process of claim 15, further comprising, prior to step a), chemically oxidizing a cholic acid (CA) of formula (2)
in which R has the meanings given above to dehydrocholic acid (DHCA) of formula (3)
in which R has the meanings given above.

### Claim 30 (depends on 15)

The process of claim 15, wherein step a) is carried out in the presence of and with the consumption of NADH and/or NADPH.

### Claim 31 (depends on 15)

The process of claim 15, further comprising purifying the ursodeoxycholic acid (UDCA) of formula (1).

### Claim 32

A nucleic acid molecule comprising a nucleotide sequence encoding a 7β-HSDH mutant, which catalyzes at least the stereospecific enzymatic reduction of a 7-ketosteroid to the corresponding 7-hydroxysteroid, wherein the mutant has at least 90% sequence identity to SEQ ID NO:2 and at least one mutation in the sequence motif VMVGRRE corresponding to positions 36 to 42 of SEQ ID NO:2, wherein the mutation is selected from the group consisting of:
a) the single mutation G39X1;
b) the single mutation R40X2;
c) the double mutation G39X1 R40X2
d) the double mutation R40X2 R41X3;
e) the double mutation G39X1 R41X3; and
f) the triple mutation G39X1 R40X2 R41X3; wherein each of X1, X2 and X3 can be the same or different and stands for mutated amino acid residues.

### Claim 33 (depends on 32)

A recombinant microorganism comprising at least one nucleic acid sequence coding for the mutant of claim 32, at least one corresponding expression cassette, or at least one corresponding vector.

### Claim 34

A recombinant microorganism that simultaneously expresses:
a) 7β-HSDH (wild type), an NADP+-accepting FDH mutant and/or the corresponding FDH wild type; or
b) which is capable of simultaneous expression of 7βHSDH (wild type)and a GDH.
